Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT06945484
Official study title

PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study

Study summary

This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPrecision Exercise Regimen for Cancer Care (PERCC)

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 3, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of Utah

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
University of Utah
Interventions being studied
Other: Precision Exercise Regimen for Cancer Care (PERCC)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
Treatment approach
Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Ages 18 and older at time of diagnosis
  • Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC)
  • Patient receives either neoadjuvant chemotherapy or immunotherapy and surgery
  • Patient able to follow direction and complete questionnaires in English or Spanish
  • Patient agrees to complete the PERCC intervention
Reasons someone may not be able to joinExclusion criteria
  • Morbidly obese (BMI \>40 kg/m2 ) or anorexic (BMI \<17.5 kg/m2 )
  • Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance
  • Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer)
  • Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Texas Medical Branch at GalvestonGalveston, Texas
  • Huntsman Cancer InstituteSalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 3, 2026. Always confirm current availability with the study team.

View original record ↗